Quick answer: Men’s health declines in testosterone, sexual function, prostate health, and cardiovascular risk are not inevitable — they are driven by insulin resistance, adipose aromatase excess, toxin-mediated endocrine disruption, sleep deficiency, and micronutrient depletion that functional medicine can systematically address.
Men’s health receives disproportionately little preventive attention despite men dying 5 years younger than women on average and having higher rates of cardiovascular disease, suicide, substance abuse, and occupational injury. Functional medicine for men addresses the root causes of hormonal decline, sexual dysfunction, prostate disease, and metabolic deterioration — integrating endocrinology, urology, cardiology, and nutritional biochemistry in a personalized preventive framework.
Testosterone Decline: Causes, Testing, and Optimization
Testosterone declines approximately 1–2% per year after age 30 — a “late-onset hypogonadism” trajectory affecting 30–40% of men by age 70. More importantly, Travison et al. (2007, Journal of Clinical Endocrinology & Metabolism) documented a population-level testosterone decline of 17% per decade independent of age — meaning a 60-year-old man today has significantly lower testosterone than a 60-year-old in 1987. This is not aging alone; it reflects environmental, metabolic, and lifestyle drivers.
Mechanisms of testosterone decline: (1) Adipose aromatase — body fat contains aromatase enzyme that converts testosterone to estradiol. Men with BMI >30 can have testosterone 40% lower and estradiol 50% higher than lean men. Central adiposity and insulin resistance are the most modifiable testosterone drivers — 10% weight loss often produces 30–100 ng/dL testosterone improvement. (2) Endocrine disruptors — phthalates (DEHP, DBP) are anti-androgenic: Meeker et al. (2010, Epidemiology) found highest phthalate urinary metabolites associated with 24% lower testosterone and altered LH/FSH signaling in men. BPA acts as an estrogen mimic; organochlorine pesticides competitively bind androgen receptors. (3) Sleep deficiency: Leproult & Van Cauter (2011, JAMA) — 5 hours sleep for 7 days reduced daytime testosterone 15%. (4) Zinc and magnesium deficiency: anabolic minerals that impair HPG axis signaling when deficient.
Testosterone testing: total testosterone alone is insufficient — free testosterone (the bioavailable fraction, approximately 2–3% of total) is the clinically relevant measure. Sex hormone binding globulin (SHBG) sequesters testosterone; elevated SHBG (from thyroid disease, liver disease, aging) reduces free testosterone despite “normal” total testosterone. Complete panel: total testosterone (8 AM fasting, twice confirmed), free testosterone (calculated from total T + SHBG + albumin), estradiol (E2, should be 20–30 pg/mL in men), SHBG, LH and FSH (distinguish primary from secondary hypogonadism), prolactin (elevated prolactin suppresses GnRH/LH), thyroid panel (hypothyroidism reduces testosterone), PSA and CBC before initiating TRT.
Testosterone Replacement Therapy: Evidence and Safety
The TRAVERSE trial (Lincoff 2023, NEJM) — 5,204 men with hypogonadism and elevated cardiovascular risk — definitively resolved the TRT cardiovascular safety controversy: testosterone therapy was non-inferior to placebo for MACE (major adverse cardiovascular events) at median 33 months. This was the landmark trial that ended a decade of prescribing hesitation based on earlier observational data. TRT also significantly improved sexual function, physical function, bone mineral density, and quality of life vs. placebo in the companion trials (TRAVERSE sexual function, physical function substudy).
TRT modalities and comparison: transdermal testosterone gel/cream (avoids first-pass metabolism, maintains stable serum levels, risk of transference to partners/children), testosterone cypionate/enanthate injection (most common: 100–200mg IM every 1–2 weeks, or more physiological 50–70mg/week to avoid supraphysiological peaks), testosterone undecanoate injection (Aveed/Nebido — every 10–14 weeks, avoiding peaks/troughs), and subcutaneous pellets (3–6 month duration, invasive to insert/remove). Monitoring: hematocrit (polycythemia risk — target <52%), PSA, testosterone levels, estradiol, blood pressure. Anastrozole or exemestane may be required if estradiol elevates above 40–50 pg/mL causing symptomatic estrogen excess (gynecomastia, fluid retention, libido paradoxically worsened).
Natural Testosterone Optimization Protocol
Before initiating TRT, functional optimization should be exhausted: resistance training (high-intensity compound movements — Kraemer 1992 showed acute testosterone elevations of 30–50% post-training, with long-term improvements in HPG axis sensitivity), weight loss (each 10% body weight reduction associated with 30–100 ng/dL testosterone increase), zinc optimization (Prasad 1996, Nutrition — zinc-restricted men had 73% testosterone decline; zinc repletion restored levels), vitamin D (Pilz 2011, Hormone and Metabolic Research RCT — 3,332 IU/day for 12 months increased testosterone 25.2% vs. placebo), magnesium (significant correlation between RBC magnesium and free testosterone — Cinar 2011, Biological Trace Element Research), sleep (7–9 hours consistently — each hour of sleep deficit reduces testosterone 15%), and stress reduction (cortisol competitively inhibits testosterone at the receptor level).
Ashwagandha (KSM-66 extract): Wankhede et al. (2015, Journal of the International Society of Sports Nutrition) RCT — 57 men with chronic stress, ashwagandha 300 mg twice daily for 8 weeks vs. placebo: testosterone increased 17% (p<0.05), muscle strength improved, and cortisol reduced 28%. Tongkat ali (Eurycoma longifolia): Hamzah & Yusof (2003) — 400mg/day increased testosterone 47% in male athletes at 5 weeks. Fadogia agrestis (traditional West African herb) — significantly elevated testosterone in rat studies via testicular testosterone production stimulation; limited human data but gaining popularity. Fenugreek: Wankhede 2016 RCT — 600mg/day significantly increased total and free testosterone and improved exercise performance over 8 weeks.
Erectile Dysfunction: Vascular, Neurological, and Hormonal Drivers
Erectile dysfunction (ED) is a biomarker of systemic vascular health — the penile arteries (1–2mm diameter) develop atherosclerosis before the coronary arteries (3–4mm) due to smaller luminal size and lower threshold for functional impairment. Thompson et al. (2005, Journal of the American College of Cardiology) demonstrated that ED predicts cardiovascular events by 2–5 years, allowing targeted cardiovascular risk reduction in this pre-event window. Functional assessment: determine whether ED is primarily vascular (endothelial dysfunction → NO deficiency → impaired penile vasodilation), neurogenic (diabetic neuropathy, pelvic surgery), hormonal (testosterone/estradiol imbalance, thyroid, prolactin), or psychogenic.
Endothelial nitric oxide pathway for ED: L-arginine (substrate for eNOS) + L-citrulline (recycles to arginine, avoiding first-pass liver metabolism) combination significantly improves ED. Cormio et al. (2011, Urology) RCT: L-citrulline 1.5g/day for 1 month significantly improved erection hardness scores in mild ED, with 50% success rate. Panax ginseng (Korean red ginseng) — ginsenosides activate eNOS and have phosphodiesterase-5 inhibition properties. Jang et al. (1995, Journal of Urology) meta-analysis: Panax ginseng significantly improved erectile function vs. placebo in multiple RCTs. Pomegranate juice: Sharma et al. (2006, International Journal of Impotence Research) RCT: pomegranate juice 8oz/day for 4 weeks significantly improved erectile function scores vs. placebo, attributed to polyphenol antioxidant NO preservation.
Prostate Health: Cancer Prevention Beyond Screening
Prostate cancer affects 1 in 8 men in their lifetime. Functional medicine approaches prostate cancer prevention through the same hormonal, metabolic, and inflammatory mechanisms that drive BPH. Ornish et al. (2005, Journal of Urology) RCT — 93 men with biopsy-confirmed early prostate cancer randomized to intensive lifestyle intervention (vegan diet + exercise + stress reduction + social support) vs. active surveillance: PSA decreased 4% vs. increased 6% in controls at 12 months, with superior tumor growth inhibition serum markers. The first RCT demonstrating lifestyle intervention can slow prostate cancer progression.
Lycopene from cooked tomatoes (Giovannucci 1995, JNCI — 47,355 men, highest lycopene intake associated with 35% lower prostate cancer risk), selenium (Clark 1996 Nutritional Prevention of Cancer trial — selenium 200 mcg/day reduced prostate cancer incidence 63%, though SELECT trial with l-selenomethionine form found no benefit — form matters), sulforaphane from broccoli sprouts (Traka 2008, PLoS ONE — altered prostate gene expression toward anti-cancer patterns within 12 months), and green tea EGCG (Bettuzzi 2006, Cancer Research — 400mg EGCG/day reduced prostate cancer incidence 90% in high-risk men with HGPIN over 12 months — remarkable effect size). 4Kscore or PHI blood tests reduce unnecessary biopsies 30–40% for elevated PSA workup.
Metabolic Syndrome and Cardiovascular Risk in Men
The 5 components of metabolic syndrome (central obesity, elevated TG, low HDL, elevated BP, elevated fasting glucose) confer 3× cardiovascular risk and 5× T2D risk. Men reach metabolic syndrome threshold 10–15 years earlier than women, driving the earlier cardiac event age. Functional cardiovascular testing beyond standard lipids: ApoB (each particle of VLDL/IDL/LDL/Lp(a) carries one ApoB molecule — superior predictor of ASCVD vs. LDL-C), Lp(a) (20% of men have genetically elevated Lp(a) — independent CVD risk factor not addressed by statins), hsCRP + IL-6 (inflammatory load), homocysteine (independent risk factor — reducible with B vitamins), and TMAO (Wang 2011 Nature — gut microbiome-derived marker of CVD risk from red meat metabolism, reducible by reducing TMAO-generating bacteria).
ApoE genotyping identifies high-risk men who respond differently to dietary fat: ApoE4 carriers show 30–40% higher LDL elevation from saturated fat and require stricter low-saturated fat protocols. Coronary artery calcium (CAC) scoring: zero calcium score (in men <65) is associated with <1% 10-year cardiovascular event risk — the most powerful negative predictor available, potentially justifying statin holiday. CAC score >100 warrants aggressive risk factor management regardless of traditional risk calculators. Combining CAC + ApoB + Lp(a) provides the most accurate cardiovascular risk stratification for men.
Ready to take a comprehensive approach to your men’s health — testosterone, cardiovascular risk, prostate, and metabolic optimization — rather than waiting for problems to develop? The Private Practice offers advanced functional men’s health evaluations. Call (810) 206-1402 to get your comprehensive men’s health assessment.
What are normal testosterone levels by age?
Total testosterone reference ranges (ng/dL): ages 20–39: 300–1,080 ng/dL (optimal functional range 600–900 ng/dL); ages 40–59: 300–890 ng/dL (functional medicine optimal 500–800 ng/dL); ages 60+: 300–720 ng/dL. More important than total testosterone is free testosterone (1.5–2.5% of total): below 50–60 pg/mL is functionally low regardless of total testosterone. Symptoms matter as much as numbers — testosterone below 350 ng/dL with symptoms (fatigue, low libido, reduced morning erections, mood changes, reduced muscle, increased body fat) warrants treatment discussion even if technically “in range.” Travison et al. (2007) documented population-level testosterone 17% lower per decade — current reference ranges may be anchored to an increasingly unhealthy population baseline.
Can you increase testosterone naturally without TRT?
Yes — substantial increases are achievable through functional optimization. Documented natural testosterone increases: weight loss from metabolic syndrome (10% weight loss → 30–100 ng/dL increase), vitamin D optimization (Pilz 2011 RCT — 3,332 IU/day increased testosterone 25.2%), zinc repletion (Prasad 1996 — zinc restriction caused 73% testosterone decline; repletion restored levels), optimizing sleep to 7–9 hours (Leproult 2011 JAMA — 5 hours/night for 1 week reduced testosterone 15%), resistance training compound movements (Kraemer 1992 — acute 30–50% elevations post-training), ashwagandha KSM-66 (Wankhede 2015 — 17% increase in 8 weeks with cortisol reduction), and reducing endocrine disruptors (phthalates, BPA, organochlorides from diet and environment).
Is TRT safe for the heart?
The TRAVERSE trial (Lincoff 2023, NEJM) definitively answered this: TRT in men with hypogonadism and existing or high-risk cardiovascular disease was non-inferior to placebo for MACE (heart attack, stroke, CV death) at median 33-month follow-up in 5,204 patients. This large, well-designed trial resolved a decade of controversy. Caveats: TRT increases hematocrit (polycythemia risk — monitor and dose-adjust to maintain hematocrit <52%), and in the TRAVERSE trial there was a numerically higher rate of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism, and acute kidney injury in the testosterone arm — warranting monitoring. Overall, TRT appears cardiovascularly safe in appropriately selected men under proper medical supervision.
What causes erectile dysfunction in young men?
ED in men under 40 (affecting 18–25% of young men seeking ED treatment) has different root causes than in older men. Primary causes: (1) Psychogenic — performance anxiety, relationship stress, depression, pornography-associated ED (reduced real-world arousal due to dopamine dysregulation); (2) Hormonal — hypogonadism, elevated estradiol (from aromatase/obesity/endocrine disruptors), hyperprolactinemia, thyroid dysfunction; (3) Cardiovascular — early-onset endothelial dysfunction from metabolic syndrome, smoking, or glycemic variability; (4) Neurogenic — pelvic floor dysfunction (hypertonic pelvic floor compressing pudendal nerve); (5) Medications — SSRIs, beta-blockers, finasteride (Post-Finasteride Syndrome). Comprehensive evaluation including hormones, metabolic markers, and pelvic floor assessment identifies treatable root causes in most young men with ED.